Aims-To establish whether PAb248 recognises human p53 as weli as murine p53 and if so, to determine its distribution in normal tissues. Methods-The ability of PAb248 to recognise human p53 was established by analysis of the human osteosarcoma derived Saos-2 celil line, which lacks the p53 gene, before and after transfection with p53 cDNA, using western blotting and immunoprecipitation. Immunostaining on normal tissues and cell lines was carried out using an immunoperoxidase technique. The two anti-p53 antibodies PAb 240 and DO-7 were used as controls.
recognises human p53 as weli as murine p53 and if so, to determine its distribution in normal tissues. Methods-The ability of PAb248 to recognise human p53 was established by analysis of the human osteosarcoma derived Saos-2 celil line, which lacks the p53 gene, before and after transfection with p53 cDNA, using western blotting and immunoprecipitation. Immunostaining on normal tissues and cell lines was carried out using an immunoperoxidase technique. The two anti-p53 antibodies PAb 240 and DO-7 were used as controls.
Results-The anti-p53 PAb248 monoclonal antibody stained the Saos-2 cell line after, but not before, transfection with p53 cDNA. Both western blots and immunoprecipitations performed with this antibody revealed a 53 000 molecular weight band. With immunostaining, this antibody detects p53 protein in most lymphoid and human epithelial cells in a cytoplasmic-perinuclear localisation that has not been described before. In the same tissues nuclear staining could be seen in a few scattered cells using the PAb240 antibody. The topographical distribution of wild type p53 was not related to proliferating areas but, rather, to short-lived populations of cells. Conclusions-Immunostaining of wild type p53 is demonstrable not only in its nuclear form using antibody PAb240 but also in its common cytoplasmic-perinuclear localisation in normal tissues using the PAb248 monoclonal antibody. This opens up new possibilities for its study in both physiological and pathological conditions. lymphocytes.4 During the course of our investigation of p53 expression in several human tumours we noticed that the PAb248 antibody appeared to give results discordant with those obtained with other antibodies on neoplastic tissues (Pezzella et al unpublished data) and, furthermore, to produce staining on normal tissue present in the sections.
C( Clin
The PAb248 monoclonal antibody was believed to be specific for murine p536 but since it recognises an epitope highly preserved between mouse and man6 we believed that it might also identify human p53, perhaps in a previously unrecognised form. This study was designed to establish whether PAb248 recognises human p53 and if so, its distribution in normal human tissues. Saos-2 cells obtained from the ATCC (Rockville, Maryland) were transfected with pCMV-neo-Bam plasmid carrying either the wild type pC53-SN3 or the mutated pC53-SCX3 p53 cDNA16 by electroporation, using a Bio-Rad instrument under the following conditions. Cells (106) in 400 pl RPMI culture medium containing 5% fetal calf serum were incubated directly in the electroporation cell (10 minutes on ice) with 10 ug of plasmid previously electroporated. Cells were transferred in Petri dishes and cultured with 400 ng/ml G418 (Gibco). Colonies were tested for p53 protein expression.
Methods
Immunostaining was performed by the immunoperoxidase technique, as described before. 7 PAb240 and PAb248 antibodies were tested on paraffin wax embedded sections after microwave pretreatment according to the method of Cattoretti et al. ' 8 Briefly, sections were dewaxed in the usual way, then placed in a glass container containing a 001M solution of sodium citrate. The slide container was placed in a microwave oven and heated at 700W (equivalent) twice for five minutes before being transferred to TRISbuffered saline (TBS) and continuing the immunocytochemistry as usual.
Results
PAb248 recognises human p53 by immunoblotting ( fig 1A) and by immunoprecipitation-immunoblotting ( fig 1B) . Its ability to recognise specifically human p53 is further demonstrated by its failure to stain the human osteosarcoma Saos-2 cell line (which lacks p53 coding exons'0) (figs 2A and B) .
However, after transfection with either the wild type or the mutant gene ( figs 2C and D 
Discussion
In this study we have shown that p53 is detectable in many cells from normal human tissues by immunostaining, and that the protein in these cells is present in two forms: cytoplasmic-perinuclear, as stained by PAb248; and nuclear, this pattern being only occasionally detectable, with PAb240.
This cytoplasmic-perinuclear localisation has not been described before in normal human tissues. However, it is not a total surprise because of its description in an embryonic murine cell line3 and the evidence for a putative cytoplasmic protein able to link with p53. '9 Furthermore, perinuclear staining was described in the human breast cancer cell line MDA 157 by Bartek et aP0 by immunostaining with PAb240. The authors comment that although this pattern of staining could have been due to the presence of a protein crossreacting with PAb240, this is unlikely, and that it might instead be caused by the presence of perinuclear p53. They support this conclusion on the grounds that perinuclear location is characteristic of centrosomes and that it has been reported that, "p53 can bind to murine p34cdc2 and that p34 cdc2 is present in the centrosome."" They also point out that on the same cell line staining with two other anti-p53 antibodies (PAb421 and PAb180I) was negative and consequently if the protein in question is p53, it is "a p53 molecule which has lost both the PAb421 and PAb1801 epitopes".'' Our findings strongly support their view that the p53 protein molecule exists in different conformations, and show that one of these has a high affinity for PAb248.
Nuclear staining for p53 in occasional normal cells has been reported both in proliferating germinal centre cells2' and quiescent cells, such as epithelial parabasal cells of the 
